> Ask the expert: Triple-negative breast cancer

Ask the expert: Triple-negative breast cancer

with Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI

Overhead view of desk with open laptop and person writing in a notebook

Date and Time

Thu, Mar 02, 2023 7:00 pm to 8:15 pm ET

Location

Virtual

Cost

Free

Watch recording

Date and Time

Thu, Mar 02, 2023 7:00 pm to 8:15 pm ET

Location

Virtual

Cost

Free

Watch recording
featured_paragraph

Triple-negative breast cancer (TNBC) makes up about 10% to 15% of breast cancer diagnoses and tends to be more aggressive than other breast cancers.

general_content

Dr. Foluso Ademuyiwa answers questions about symptoms, side-effects, and treatment options for early-stage and metastatic TNBC.

on_this_page

On this page

video
audio_embed
Back to top
speakers_feature

About our speaker

Foluso Olabisi Ademuyiwa headshot

Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI

Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI, is a breast medical oncologist and associate professor at Washington University in St. Louis. She is an expert in the management of all types of breast cancer. She provides patient-centered care as part of a multidisciplinary breast cancer team. Dr. Ademuyiwa is actively involved in research on triple-negative breast cancer and racial disparities in breast cancer research and serves as principal investigator on multiple clinical trials.

Learn more
Back to top
3 Tier Sponsors

Thank you to our sponsors

related_resources_article_carousel

Related resources

Dealing with negative comments

01/23/25 | BY: Lisa Carey

Get tips on how to manage people who have opinions about your breast cancer treatment.

Read More
 | 6 Min. Read |

Immunohistochemistry (IHC) tests

11/15/24 | BY: Regina Hampton

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

Read More
 | 7 Min. Read

Triple-negative

12/19/23 | BY: Reshma L. Mahtani

Triple-negative breast cancers (TNBC) test negative for hormone and HER2 receptors. About 10% to 15% of breast cancers are triple-negative.

Read More
 | 13 Min. Read |

Triple-negative metastatic breast cancer

05/01/23 | BY: Rita Nanda

Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.

Read More
 | 11 Min. Read |

Sacituzumab govitecan

02/03/23 | BY: Stephanie Graff

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with several types of metastatic breast cancer.

Read More
 | 5 Min. Read |

Targeted therapy for triple-negative breast cancer

01/01/23 | BY: Zanetta Lamar

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

Read More
 | 4 Min. Read |

Follow-up care for TNBC

04/18/18 | BY: Lisa Carey

Learn what follow-up care may be needed and what it entails following a treatment for triple-negative breast cancer.

Read More
 | 4 Min. Read |

Risks and fear of recurrence

04/18/18 | BY: Lisa Carey

Find out about activities and emotional support to help quell anxiety and worry after treatment for triple-negative breast cancer. 

Read More
 | 3 Min. Read
Back to top
upcoming_events

Upcoming Events

Navigating the changing landscape of early-stage breast cancer

Wed, May 21, 2025

Learn More

Newsflash: Updates from the 2025 ASCO Annual Meeting

Thu, Jun 12, 2025

Learn More

2025 Butterfly Ball

Sat, Nov 08, 2025

Learn More
View All Events View Past Events
stay_connected

Stay connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.